Granules India Limited completes cGMP Audit at its Chantilly Site

Granules India Limited today announced that its wholly-owned subsidiary, Granules Pharmaceuticals, Inc. (GPI), located in Chantilly, Virginia, US, has completed a routine current Good Manufacturing Practices (cGMP) audit by the US Food and Drug Administration (FDA) with four Form 483 observations.

This inspection was conducted from March 30 to April 3, 2026 and marks the second US FDA inspection at the Chantilly facility in last one year.

The observations are related to procedural matters and no data integrity-related observations were reported during the inspection.

Granules remains committed to maintaining the highest standards of quality, safety, and regulatory compliance and will address the observations raised by the US FDA within the stipulated timelines.

Shares of Granules India Limited was last trading in BSE at Rs. 614.00 as compared to the previous close of Rs. 628.20. The total number of shares traded during the day was 49595 in over 2348 trades.

The stock hit an intraday high of Rs. 622.00 and intraday low of 601.60. The net turnover during the day was Rs. 30346971.00.

Source : Equity Bulls

Keywords

GranulesIndia INE101D01020 GRANULESPharmaceuticals Inc USFDA cGMPAudit Form483 4Observations